Cargando…

Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy

INTRODUCTION: Traditional therapeutic approaches for the treatment of advanced non-small-cell lung cancer (NSCLC) are based on chemotherapy. However, the discovery and understanding of oncogenic driver alterations has led to the development of targeted therapies that have substantially improved pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Que, Dan, Zou, Hongbo, Mao, Bijing, Zhang, Huan, Liang, Wei, Liu, Qin, Ke, Leiyu, Guo, Lijie, Xie, Qichao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745108/ https://www.ncbi.nlm.nih.gov/pubmed/36523965 http://dx.doi.org/10.3389/fonc.2022.967675

Ejemplares similares

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Ribonucleic acid-binding protein CPSF6 promotes glycolysis and suppresses apoptosis in hepatocellular carcinoma cells by inhibiting the BTG2 expression
por: Liu, Yang, et al.
Publicado: (2021)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
por: Zhai, Xiaoqian, et al.
Publicado: (2023)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Case Report: ALK-Positive Histiocytosis With KIF5B-ALK Fusion in Cerebrum-Disseminated Lesions in a Child
por: Guo, Yi, et al.
Publicado: (2022)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
por: Cao, Jun, et al.
Publicado: (2022)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
por: Shi, Liang, et al.
Publicado: (2023)

Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy
por: Yahara, Katsuya, et al.
Publicado: (2013)

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
por: Xiao, Andrew, et al.
Publicado: (2023)

Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
por: Han, Dan, et al.
Publicado: (2022)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
por: Ou, Kai, et al.
Publicado: (2021)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
por: Poddubskaya, Elena, et al.
Publicado: (2019)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus
por: Abdelhakam, D., et al.
Publicado: (2020)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
por: Wen, Zhengqi, et al.
Publicado: (2021)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
por: Ye, Zhifeng, et al.
Publicado: (2023)

ALK Inhibitors, a Pharmaceutical Perspective
por: Ardini, Elena, et al.
Publicado: (2012)

Targeting ALK in Neuroendocrine Tumors of the Lung
por: Akhoundova, Dilara, et al.
Publicado: (2022)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab
por: Horibe, Yuki, et al.
Publicado: (2021)

A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer
por: Zhang, Zhongyan, et al.
Publicado: (2023)

Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report
por: Tan, Li, et al.
Publicado: (2023)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
por: Zhu, Zhe, et al.
Publicado: (2023)

The role of demethylase AlkB homologs in cancer
por: Li, Qiao, et al.
Publicado: (2023)

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
por: Ma, Lin, et al.
Publicado: (2022)

Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib
por: Mahuad, Carolina Valeria, et al.
Publicado: (2016)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gj3ktsb1njujbvupegbjda39kf